Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01146041 | Bioequivalence Study of Rivastigmine Capsules 1.5 mg of Dr.Reddy's Under Fed Conditions | PHASE1 | COMPLETED | 44 | — | — | Feb 1, 2004 | Apr 1, 2004 | Jun 17, 2010 | - | — |
| NCT01146067 | Bioequivalence Study of Rivastigmine 1.5 mg Capsules Under Fasting Conditions | PHASE1 | COMPLETED | 44 | — | — | Jan 1, 2004 | Feb 1, 2004 | Jan 13, 2012 | - | — |
| Arm | Type | Description |
|---|---|---|
| Rivastigmine | EXPERIMENTAL | Rivastigmine capsules 1.5 mg of Dr.Reddy's Laboratories Limited |
| exelon | ACTIVE_COMPARATOR | Exelon 1.5 mg capsules of Novartis |
| Name | Type | Description |
|---|---|---|
| Rivastigmine | DRUG | Rivastigmine 1.5 mg Capsules |
Inclusion criteria * Subjects enrolled in this study will be members of the community at large. The recruitment advertisements may use various media types (e.g. radio, newspaper, Anapharm Inc. Web site, Anapharm Inc. volunteer's database). Subjects must meet all of the following criteria in order t...